Patents Assigned to Quentis Therapeutics, Inc.
  • Publication number: 20200157079
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: August 16, 2019
    Publication date: May 21, 2020
    Applicant: Quentis Therapeutics, Inc.
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • Publication number: 20190276434
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Application
    Filed: December 1, 2017
    Publication date: September 12, 2019
    Applicant: Quentis Therapeutics, Inc.
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • Patent number: 10392367
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 27, 2019
    Assignee: Quentis Therapeutics, Inc.
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole